XM does not provide services to residents of the United States of America.

Dow starts review of some Europe assets, Q3 exceeds estimates



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Dow starts review of some Europe assets, Q3 exceeds estimates</title></head><body>

Adds details and background in paragraphs 4-8

Oct 24 (Reuters) -Chemical company Dow DOW.N said on Thursday it has begun a review of some of its European assets even as its third-quarter profit beat estimates on higher North America demand for industrial items such as polyethylene used in packaging.

Dow said the review was necessitated by weak demand recovery and competitive regulatory policies. Its shares rose 1.7% to $52.37 in premarket trading.

The company's review will primarily focus on assets in its polyurethane business, CEO Jim Fitterling said. Dow aims to complete the review by mid-2025.

Lower prices and volumes in polyurethane partly resulted in the underperformance of its industrial intermediates and infrastructure segment, which saw a 2% drop in net sales.

The company said overall demand in Europe and China remained muted.

"Meaningful recovery has yet to materialize in Europe and China. In addition, Europe's regulatory environment has led to increasing challenges across many sectors and value chains," Fitterling said.

Quarterly net sales from its packaging and specialty plastics segment, its largest by revenue, rose 1.1% to $5.52 billion, led by higher polyethylene sales for industrial, consumer, and flexible food packaging.

Quarterly revenue rose 1.4% to $10.88 billion, despite operations taking a hit due to Storm Beryl. Analysts on average were expecting $10.65 billion.

Dow said it was reducing low-value merchant order exposure by shutting down its Freeport unit in 2025, which represents about 20% of North America industry capacity.

Its adjusted profit of 47 cents per share exceeded market expectations by a cent, according to data compiled by LSEG.



Reporting by Tanay Dhumal in Bengaluru; Editing by Arun Koyyur

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.